Odevixibat Pregnancy and Lactation Surveillance Program: A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Odevixibat During Pregnancy and/or Lactation
Latest Information Update: 07 Oct 2024
At a glance
- Drugs Odevixibat (Primary)
- Indications Alagille syndrome; Biliary atresia; Cholestasis; Intrahepatic cholestasis
- Focus Adverse reactions
- Sponsors Ipsen
Most Recent Events
- 02 Apr 2024 Planned primary completion date changed from 2 Sep 2032 to 2 Sep 2031.
- 20 Feb 2024 New trial record